Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K0GF
|
||||
| Former ID |
DCL001002
|
||||
| Drug Name |
SSR-181507
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Phase 1 | [536463] | ||
| Company |
Sanofi-Aventis
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H27ClN2O3
|
||||
| Canonical SMILES |
C1CC2CC(CC1N2C(=O)C3=CC=CC=C3)CNCC4COC5=C(O4)C=C(C=C5)C<br />l
|
||||
| InChI |
1S/C24H27ClN2O3/c25-18-6-9-22-23(12-18)30-21(15-29-22)14-26-13-16-10-19-7-8-20(11-16)27(19)24(28)17-4-2-1-3-5-17/h1-6,9,12,16,19-21,26H,7-8,10-11,13-15H2/t16?,19-,20+,21-/m0/s1
|
||||
| InChIKey |
VDQJQKSTXHXBME-DTHFOOOUSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Modulator | ||
| D(2) dopamine receptor | Target Info | Modulator | |||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.